Skip to main content

Alembic Pharma share price gains after tentative FDA nod for diabetes drug

 The firm has got the nod for empagliflozin and linagliptin tablets. Empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes.

Alembic Pharmaceuticals share price gained 3 percent intraday on August 27 after the pharma company received a tentative nod for the US drug regulator for empagliflozin and linagliptin tablets.

The company has received US Food & Drug Administration (USFDA) tentative approval for empagliflozin and linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg. Alembic now has a total of 130 ANDA approvals (113 final approvals and 17 tentative approvals) from the FDA, the company said in an exchange filing.

Empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease. However, the effectiveness of empagliflozin and linagliptin tablets in reducing the risk of cardiovascular death in adults with type 2 diabetes mellitus and cardiovascular disease has not been established, the company said.

Empagliflozin and linagliptin tablets (10 mg/5 mg and 25 mg/5 mg) had an estimated market size of $244 million for twelve months ending June 2020, the company said, citing IQVIA data.



The stock, which has gained 57 percent in the past six months, was trading at Rs 1,022.40, up Rs 31.60, or 3.19 percent. It has touched an intraday high of Rs 1,024.45 and an intraday low of Rs 990.80.

The drug company on August 25 said its joint venture partner Aleor Dermaceuticals received final approval from the US regulator for Desonide lotion used to treat a variety of skin conditions. The approved Abbreviated New Drug Application (ANDA) is therapeutically equivalent to the reference listed drug product DesOwen Lotion, 0.05 percent, of Galderma Laboratories LP.



According to Moneycontrol SWOT Analysis powered by Trendlyne, the company has zero promoter pledge with book value per share improving for the past two years

Moneycontrol technical rating is bullish with moving averages and technical indicators being bullish.

Disclaimer: The views and investment tips expressed by experts on moneycontrol.com are their own and not those of the website or its management. Moneycontrol./SD Solutions com advises users to check with certified experts before taking any investment decisions.

Labels:

Comments

Post a Comment

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...
Post a Comment
Read more

Taking Stock | Profit-booking pulls Nifty below 14,450; Sensex drops 549 points

  All the sectoral indices ended in the red with IT and PSU bank indices falling 2 percent each. The market remained under pressure on January 15 on the back of profit-booking across sectors amid weak global cues. At close, the Sensex was down 549.49 points or 1.11% at 49,034.67, and Nifty was down 161.90 points or 1.11% at 14,433.70. "The market witnessed profit-booking and following global trends. Nifty continues to resist 14,600 and has taken a dip towards 14,360. If the market closes below 14,380 levels, we might see a correction till the levels of 14,180-14,200. Momentum indicators like RSI, MACD are indicating a small correction in the markets," said Ashis Biswas, Head of Research at CapitalVia Global Research. All the sectoral indices ended in the red with IT and PSU bank falling 2 percent each. Broader markets performed in line with the main indices with BSE Midcap and Smallcap indices falling 1 percent each. Tech Mahindra, GAIL, HCL Tech, Wipro and ONGC...
Post a Comment
Read more

Similar to 2020, D-Street is at record high ahead of Budget 2021; will history repeat itself?

  Experts are of the view that a repeat of 2020 or what happened in March might not be possible but some consolidation cannot be ruled out. Back in March when everyone wanted to write-off 2020 from their books, hope and liquidity supported markets and investor sentiment. Nobody thought that after touching a 3-year low in March 2020, benchmark indices would give double-digit returns by the end of the year. The S&P BSE Sensex and Nifty50 rallied by about 15 percent in 2020 and the big outperformance came from the small and midcap stocks. The rally is still continuing in 2021. The S&P BSE Sensex, which climbed Mount 49K, is up over 3 percent while the Nifty50 is up over 4 percent so far in January. Sensex scaling the 49,000-mark and Nifty50 touching 14,500 levels ahead of the Budget 2021 could make anyone cautious about the strength of the rally. Back in January 2020, both Sensex and Nifty touched fresh highs ahead of Budget, and then the market fell like a pack of cards. The ...
Post a Comment
Read more